Medical Design and Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech

Boehringer Ingelheim to Launch RE-ALIGNâ„¢ Trial to Evaluate Dabigatran Etexilate in Patients with Mechanical Heart Valves

August 26, 2011 By Bio-Medicine.Org

RIDGEFIELD, Conn., Aug. 26, 2011 /PRNewswire/ — Boehringer
Ingelheim Pharmaceuticals, Inc. (BIPI) today announced plans to
launch RE-ALIGN™, a global, Phase II trial evaluating the
safety and pharmacokinetics of dabigatran etexilate in 400 patients
who have mechanical heart valves.(1) The 12-week study will compare
three doses of dabigatran etexilate (150mg bid, 220mg bid and 300mg
bid) to warfarin in patients with both aortic valve replacements
and mitral valve replacements.(1) A RE-ALIGN extension study will
evaluate the ongoing safety of dabigatran etexilate in this patient
population for up to 84 months.(1)

Mechanical heart valves are used to treat heart valve disease,
which occurs when one or more valves in the heart does not function
properly.(2) An estimated 2.5 percent of the American population
has heart valve disease.(3) Approximately 100,000 patients undergo
heart valve replacement in the U.S. each year,(4) 55 percent of
which are mechanical heart valves.(5) Patients with mechanical
heart valves require lifelong anticoagulation to help prevent blood
clots from forming on or around the valve.(6) A meta-analysis of 46
studies involving patients with mechanical heart valves found the
annual incidence of thromboembolism for those who are untreated to
be 8.6 percent.(7)

“Boehringer Ingelheim is committed to ongoing research that will
expand our understanding of dabigatran etexilate as a treatment
option for patients with a variety of cardiovascular and
thromboembolic conditions,” said John Smith, MD, PhD, senior vice
president for clinical development and medical affairs, Boehringer
Ingelheim Pharmaceuticals, Inc. “We are proud to announce the
launch of RE-ALIGN and plans for a RE-ALIGN extension study, to
assess dabigatran etexilate as a potential treatment option to
reduce stroke risk in patients with mechanical heart valves.”

Dabigatran etexilate was approved by the FDA in October 2010 as
the first oral anticoagulant in more

‘/>”/>

SOURCE

Related Articles Read More >

Dexcom One
How Dexcom’s portfolio goes beyond highly-anticipated next-gen G7
A portrait of Stryker executive Siddarth Satish
How Stryker includes users for product design in the digital age
A Medtronic HVAD pump opened up to show the inner workings
Medtronic investigates HVAD pump welds after patient deaths
Galien Foundation 2022 nominees
18 of the world’s most innovative medical technologies

DeviceTalks Weekly.

May 20, 2022
DeviceTalks Boston Post-Game – Editors’ Top Moments, Insulet’s Eric Benjamin on future of Omnipod 5
See More >

MDO Digital Edition

Digital Edition

Subscribe to Medical Design & Outsourcing. Bookmark, share and interact with the leading medical design engineering magazine today.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
DeviceTalks

DeviceTalks is a conversation among medical technology leaders. It's events, podcasts, webinars and one-on-one exchanges of ideas & insights.

DeviceTalks

New MedTech Resource

Medical Tubing

Enewsletter Subscriptions

Enewsletter Subscriptions

MassDevice

Mass Device

The Medical Device Business Journal. MassDevice is the leading medical device news business journal telling the stories of the devices that save lives.

Visit Website
MDO ad
Medical Design and Outsourcing
  • MassDevice
  • DeviceTalks
  • MedTech 100 Index
  • Medical Tubing + Extrusion
  • Drug Delivery Business News
  • Drug Discovery & Development
  • Pharmaceutical Processing World
  • R&D World
  • About Us/Contact
  • Advertise With Us
  • Subscribe to Print Magazine
  • Subscribe to E-newsletter
  • Attend our Monthly Webinars
  • Listen to our Weekly Podcasts
  • Join our DeviceTalks Tuesdays Discussion

Copyright © 2022 WTWH Media, LLC. All Rights Reserved. Site Map | Privacy Policy | RSS

Search Medical Design & Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech